| A21 | Defining CTL immunotherapy candidates against replication-competent and defective HIV | On-demand oral abstract session | Immunotherapy: Vaccines and antibodies |
| A21 | The balance of mucosal CD4 T cells prior to infection is associated with control of virus replication after therapeutic vaccination in SIV-infected rhesus macaques | On-demand oral abstract session | Immunotherapy: Vaccines and antibodies |
| A20 | GS-9822, a preclinical LEDGIN, displays a block-and-lock phenotype in cell culture | On-demand oral abstract session | Eliminating and silencing latency |
| A20 | Combination therapy with the broadly neutralizing antibody VRC07'523LS and the latency reversal agent Vorinostat fails to substantially reduce latent, resting CD4+ T cell infection or reduce low-level viremia | Oral abstract session with live Q&A | Eliminating and silencing latency |
| A20 | XPB degradation by Spironolactone prevents HIV-1 reactivation from latency | E-poster | Eliminating and silencing latency |
| A20 | Dasatinib inhibits provirus reactivation in patients co-infected with HIV and HCV | E-poster | Eliminating and silencing latency |
| A2 | The frequency of HLA-l alleles could influence the level of post-transmission readaptation of HIV-1 | E-poster | Viral fitness, persistence and resistance |
| A2 | Premutations could facilitate CTL escape in gag epitopes during early HIV-1 infection | E-poster | Viral fitness, persistence and resistance |
| A2 | Low-level HIV-1 viral load predicts virologic failure in antiretroviral experienced individuals in Botswana | E-poster | Viral fitness, persistence and resistance |
| A2 | High resistance mutation to cART in HIV-1 exposed infected children and recent emergence of CRF02_AG variant in Bouar, a rural environment of Central African Republic | E-poster | Viral fitness, persistence and resistance |